SCHEMBL5541508

SCHEMBL5541508

Cc1ccc(NC(=O)N2CCN(CC[C]=O)CC2)cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
TP53 P04637 3/20 0.54
FAAH O00519 1/20 0.54
HTT P42858 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 2/20 0.48
ALOX12 P18054 1/20 0.48
LMNA P02545 2/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 4/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 3/20 0.47
HPGD P15428 1/20 0.46
RECQL P46063 1/20 0.46
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546588 0.86 NPC1 (0.58) NPC1RAB9ATP53FAAHHTT
SCHEMBL5541522 0.82 NPC1 (0.61) NPC1RAB9ATP53FAAHHTT
SCHEMBL5542340 0.81 FAAH (0.59) NPC1RAB9ATP53FAAHKDM4E
SCHEMBL5536453 0.81 KMT2A (0.58) FAAHLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL5541733 0.80 FAAH (0.65) FAAHKDM4EMAPTCA12CA2
SCHEMBL5546036 0.80 MAPT (0.70) TP53FAAHALDH1A1MAPTSMN1; SMN2
SCHEMBL4559342 0.78 RAB9A (0.91) NPC1RAB9ATP53HTTL3MBTL1
SCHEMBL5544609 0.78 FAAH (0.60) FAAHLMNAMAPTSMN1; SMN2CCR2
SCHEMBL5535035 0.75 ACHE (0.66) LMNAALDH1A1SMN1; SMN2POLB
SCHEMBL9283129 0.72 RAB9A (0.65) NPC1RAB9AHTTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NPC1 2404/4885RAB9A 2824/4885TP53 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.